Tonix Pharmaceuticals (TNXP) Investor presentation summary

Commercial execution and financial position

• Launched Tonmya, a sublingual cyclobenzaprine tablet, as the first new FDA-approved fibromyalgia treatment in over 15 years, with U.S. launch in November 2025 and first commercial coverage agreement in May 2026.

• Achieved net sales of $5.1 million from launch through March 31, 2026, with 11,016 prescriptions and over 5,600 unique patients by May 2026.

• Maintains a strong cash position of $185.5 million as of March 31, 2026, with no debt and expected runway into early Q2 2027.

Product innovation and clinical pipeline

• Tonmya offers a unique, non-opioid, sublingual formulation for fibromyalgia, showing rapid, durable efficacy and a favorable safety profile in pivotal Phase 3 trials.

• Pipeline includes TNX-102 SL for major depressive disorder and acute stress disorder, TNX-4800 for Lyme disease prevention, TNX-1500 for organ transplant rejection, TNX-2900 for Prader-Willi syndrome, and TNX-1300 for cocaine intoxication.

• Multiple Phase 2 studies are planned or ongoing, with key milestones expected from mid-2026 through 2027.

Market opportunity and unmet needs

• Fibromyalgia affects over 10 million in the U.S., with high dissatisfaction and failure rates for existing therapies; Tonmya targets this large, underserved population.

• High rates of off-label opioid use persist despite lack of efficacy and increased risks, highlighting the need for safer, effective alternatives.

• TONMYA is positioned as the only marketed prescription drug for fibromyalgia, with a focused commercial strategy targeting high-prescribing healthcare providers.